Tern Plc FundamentalVR secures £7 million in new equity investment

TERN

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things technology businesses, has announced that FVRVS Limited, has undertaken a Series B fund raising round, securing £7 million in new equity investment from existing investors and a new institutional investor, at a valuation uplift of 77% from the previous book valuation of Tern’s holding.

Highlights

·    FundamentalVR has raised a total of £7 million in a Series B fund raising from existing investors and a new institutional investor, with an additional £1.2 million of convertible loan notes being converted

·    Tern has converted approximately £570,000 in loan notes and accrued interest it held in FundamentalVR into equity, in line with the terms of these loan notes, but will invest no new money in the FundamentalVR Series B

·    The FundamentalVR Series B is intended to provide FundamentalVR with funding to enable to grow in line with its strategy, including expanding its US activities

·    With the completion of the £7 million FundamentalVR Series B, including the conversion of Tern’s loan notes to equity, Tern will hold 20.0% of FundamentalVR’s equity, valued at £6.3 million at the valuation implied by the FundamentalVR Series B price

FundamentalVR Fund Raise

Prior to the FundamentalVR Series B, Tern had a holding of 26.9% in FundamentalVR, plus a loan convertible into FundamentalVR equity of £530,000 and accrued interest of £39,932.  As at 31 December 2021, the date of Tern’s last published book valuation, this holding had an audited book value of £3.6 million. 

Following the FundamentalVR Series B funding of £7 million, the conversion of Tern’s £0.53 million of loan notes and the conversion of £0.63 million of loan notes held by other investors, FundamentalVR is now valued in total at approximately £23 million on a pre-money basis and Tern now has a holding of 20.0% in FundamentalVR (before any dilution on exercise of any future FundamentalVR employee share options), with an unaudited book valuation of £6.3 million, representing a 77% uplift on the 31 December 2021 book value of Tern’s holding.

Further information on FundamentalVR

FundamentalVR delivers virtual reality haptic ‘flight simulators’ for surgery creating a safe, measurable and repeatable space to refine skills.  FundamentalVR’s goal is to transform the way surgeons prepare, practice, and refine their skills.  It has built an immersive, surgical simulation application platform, Fundamental Surgery, to provide medical professionals with the opportunity to rehearse, practice, and test themselves within a safe, controllable space that is as close to real-life as possible.

According to the latest filed financial statements for FundamentalVR, for the 12 month period ended 31 December 2020, the business recorded an increase in retained unaudited losses of £2.12 million and at that date had unaudited net assets of approximately £1.27 million.  Given the historic nature of these figures Tern does not consider this to be representative of the current business and trading performance of FundamentalVR.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Search